Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:30990...
| Class:Id | Summation:2206289 |
|---|---|
| _displayName | Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:30990... |
| _timestamp | 2014-05-28 04:52:17 |
| created | [InstanceEdit:2206283] Jassal, B, 2012-04-26 |
| modified | [InstanceEdit:2210366] Jassal, B, 2012-04-27 [InstanceEdit:2318591] Jassal, B, 2012-06-14 [InstanceEdit:2422438] Jupe, S, 2012-07-19 [InstanceEdit:2429636] Jupe, S, 2012-08-09 [InstanceEdit:2457601] Jassal, B, 2012-08-24 [InstanceEdit:2457690] Jassal, B, 2012-08-28 [InstanceEdit:2458286] Jassal, B, 2012-08-29 [InstanceEdit:5577005] Matthews, Lisa, 2014-05-28 |
| text | Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:309900) is an X-linked, recessive genetic disorder which therefore primarily affects males. MPS II was first described in 1917, by Major Charles Hunter (Hunter 1917) and is caused by a deficiency (or absence) of iduronate-2-sulfatase (IDS, MIM:300823), which would normally hydrolyse the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin. Without IDS, these GAGs accumulate in the body and are excessively excreted in urine. Although the disease was known since the early 1970s, being the first MPS to be defined clinically in humans, it wasn't until the 1990s that IDS was cloned. It is now known to be localized to Xq28 (Wilson et al. 1991) and contain 9 exons (Flomen et al. 1993) spanning approximately 24 kb (Wilson et al. 1993). Build up can occur in the liver and spleen as well as in the walls and valves of the heart (reduced hepatic and cardiac function, liver/spleen hepatosplenomegaly), airways (leading to obstructive airway disease), all major joints and bones (joint stiffness and skeletal deformities) and in brain (severe mental retardation). The rate of progression and degree of severity of the disorder can be different for each person with MPS II. Severe forms of the disorder can result in death in childhood whereas those with a "milder" form can expect to live to their 20's or 30's. Some patients even survive into their fifth and sixth decades of life (Wraith et al. 2008, Beck 2011). |
| (summation) | [Pathway:2206296] MPS II - Hunter syndrome (HS-GAG degradation) [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:30990... (2206289)
